Food and Drug Administration, Shortages of Ozempic

Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound. Her weight dropped so much that researchers reduced her dose of the treatment, called retatrutide. Still, she continued to feel too nauseous, so she decided by herself to start skipping every other dose.
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved. Zepbound is approved to treat obesity and Mounjaro is approved for diabetes. They use the same active ingredient, tirzepatide.
This weight loss drug reduces heart failure risk
A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure patients while reducing death rates.
Zepbound for Weight Loss: What to Know About This Weight Loss Drug
For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and
These Drugs Could Offset the Side Effects of Weight Loss
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
New weight loss drugs aim to promote muscle growth
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate
When online weight-loss drugs are too good to be true
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients.
The Ozempic shortage is over, a big threat to off-brand weight loss drug sellers
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA).
U.S. attorneys general forum urges FDA to act against counterfeit weight loss drugs
A bipartisan group of U.S. state and territory attorneys general is pressing the FDA to take prompt action against those threatening public health by marketing counterfeit forms of branded weight loss medications developed by Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY).
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.
Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.They cost so much partly because of ...
The next battle in the weight-loss drug war is focussed on muscle growth
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Weight-loss drugs are about to get a lot better
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.